Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. If a company's net margin is 15%, for example, that means its net income (or profit) is 15 cents for every $1 of sales the company makes. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. The analysts previously had rating of Sell. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. A value greater than 1, in general, is not as good (overvalued to its growth rate). Visit www.zacksdata.com to get our data and content for your mobile app or website. We use cookies to understand how you use our site and to improve your experience. These returns cover a period from January 1, 1988 through January 4, 2021. Zacks Style Scores Education - Learn more about the Zacks Style Scores. If, on the other hand, it went from $1.00 to 90 cents, that would be a -10% change in the consensus estimate revision. Our testing substantiates this with the optimum range for price performance between 0-20. It's calculated as earnings divided by price. View detailed financial information, real-time news, videos, quotes and analysis on Akebia Therapeutics, Inc. (NASDAQ:AKBA). Visit www.zacksdata.com to get our data and content for your mobile app or website. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock … Value Style - Learn more about the Value Style. Zacks. The (Q1) EPS Estimate Monthly Change calculates the percentage change in the consensus earnings estimate for the current quarter (Q1) over the last 4 weeks. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. * indicates the important links in the menu. Click to get this free report Akebia Therapeutics, Inc. (AKBA) : Free Stock Analysis Report Copyright 2021 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. So, as with other valuation metrics, it's a good idea to compare it to its relevant industry. Enterprise Value / Earnings Before Interest, Taxes, Depreciation and Amortization is a valuation metric used to measure a company's value and is helpful in comparing one stock to another. That means these items are added back into the net income to produce this earnings number. This is useful for obvious reasons, but can also put the current day's intraday gains into better context by knowing if the recently completed trading day was up or down. The X Industry values displayed in this column are the median values for all of the stocks within their respective industry. Others will look for a pullback on the week as a good entry point, assuming the longer-term price changes (4 week, 12 weeks, etc.) Within the VGM Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy srocks with the highest probability of success. Net Margin is defined as net income divided by sales. A stock with a P/E ratio of 20, for example, is said to be trading at 20 times its annual earnings. Copyright 2021 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. The Current Ratio is defined as current assets divided by current liabilities. Zacks Rank Education -- Learn more about the Zacks Rank akba stock: buy or sell. Log into your account. Zacks Sector Rank Education -- Learn more about the Zacks Sector Rank. Cash flow itself is an important item on the income statement. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. As of late, it has definitely been a great time to be an investor in Akebia Therapeutics, Inc. (AKBA).The stock has moved higher by 55% in the past month, while it is also above its 20 Day SMA too. Zacks Rank Education -- Learn more about the Zacks Rank Want the latest recommendations from Zacks Investment Research? The monthly returns are then compounded to arrive at the annual return. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. So be sure to compare a stock to its industry's growth rate when sizing up stocks from different groups. Seeing how a company makes use of its equity, and the return generated on it, is an important measure to look at. Over the past three months, the Zacks Consensus Estimate for AKBA's full-year earnings has moved 6.07% higher. A change in margin can reflect either a change in business conditions, or a company's cost controls, or both. Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank. See rankings and related performance below. Simply Wall St. 07:07AM : Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Path To Profitability. completeness, timeliness, or correct sequencing of any of the Information on Value investors will typically look for stocks with P/E ratios under 20, while growth investors and momentum investors are often willing to pay much more. Zacks Rank Education -- Learn more about the Zacks Rank NASDAQ data is at least 15 minutes delayed. But when compared to its growth rate, it does't have the earnings growth to justify its P/E. In general, the lower the ratio is the better. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. View Akebia Therapeutics, Inc. AKBA investment & stock information. This includes personalizing content and advertising. Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. Within the Finance Sector, it would fall into the M Industry of Banks & Thrifts. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. This is an estimated date of earnings release. In the short term (2weeks), AKBA's stock price should outperform the market by 5.90%.During that period the price should oscillate between -7.35% and +13.91%.. Momentum Style - Learn more about the Momentum Style. If the P/S ratio is 1, that means you're paying $1 for every $1 of sales the company makes. A sales/assets ratio of 2.50 means the company generated $2.50 in revenue for every $1.00 of assets on its books. The most common way this ratio is used is to compare it to other stocks and to compare it to the 10 Year T-Bill. A ratio of 1 means a company's assets are equal to its liabilities. The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. The Momentum Scorecard table also displays the values for its respective Industry along with the values and Momentum Score of its three closest peers. Zacks Ranks stocks can, and often do, change throughout the month. View Akebia Therapeutics' (NASDAQ:AKBA) earnings history, next earnings date and earnings forecasts from top-rated Wall Street analysts at MarketBeat. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. |  Privacy Policy. The scores are based on the trading styles of Value, Growth, and Momentum. If a company's expenses are growing faster than their sales, this will reduce their margins. A D/E ratio of 2 might be par for the course in one industry, while 0.50 would be considered normal for another. Akebia Therapeutics NASDAQ Updated Mar 10, 2021 10:48 PM. Using this item along with the 'Current Cash Flow Growth Rate' (in the Growth category above), and the 'Price to Cash Flow ratio' (several items above in this same Value category), will give you a well-rounded indication of the amount of cash they are generating, the rate of their cash flow growth, and the stock price relative to its cash flow. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Aside from using absolute numbers, however, you can also find value by comparing the P/E ratio to its relevant industry and its peers. A P/B of 0.5 means its selling at half its book value. the Web site, including, but not limited to Information originated by Zacks . It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500. Once again, cash flow is net income plus depreciation and other non-cash charges. Click to get this free report Akebia Therapeutics, Inc. (AKBA) : Free Stock Analysis Report There are 17 Sectors, 60 different M Industries, and 265 X Industries. The Zacks Sector Rank assigns a rating to each of the 16 Sectors based on their average Zacks Rank. It is essentially the inverse of the P/E ratio. All of those stocks are classified into three groups: Sector, M Industry and X Industry. The analyzed items go beyond simple trend analysis. Volume has increased on the last day by 2 million shares but on falling prices. The Price to Book ratio or P/B is calculated as market capitalization divided by its book value. Zacks Premium - The way to access to the Zacks Rank. The 1 Week Price Change displays the percentage price change over the last 5 trading days using the most recently completed close to the close from 5 days before. This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. For example, a regional bank would be classified in the Finance Sector. For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. The (F1) EPS Estimate Quarterly Change calculates the percentage change in the consensus earnings estimate for the current year (F1) over the last 12 weeks. Post-Market 0.02 (0.57%) Zacks Sector Rank Education - Learn more about the Zacks Sector Rank. See rankings and related performance below. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. Cash flow can be found on the cash flow statement. Growth Style - Learn more about the Growth Style. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. Cash is vital to a company in order to finance operations, invest in the business, pay expenses, etc. The Sales to Assets ratio (or Sales to Total Assets or S/TA for short) shows how much sales are generated from a company's assets. These returns cover a period from January 1, 1988 through January 4, 2021. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. A higher number is better than a lower number. ... (NASDAQ:AKBA) Stock A Year Ago, You Could Pocket A 132% Gain Today. If you wish to go to ZacksTrade, click OK. Volume is a useful item in many ways. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet. Regal Wallet > Blog > Uncategorized > akba stock: buy or sell. This item is updated at 9 pm EST each day. Note; companies will typically sell for more than their book value in much the same way that a company will sell at a multiple of its earnings. For example, a cash/price ratio, or cash yield, of .08 suggests an 8% return or 8 cents for every $1 of investment. Zacks Rank Education -- Learn more about the Zacks Rank Since cash can't be manipulated like earnings can, it's a preferred metric for analysts. There may be delays, omissions, or inaccuracies Projected EPS Growth looks at the estimated growth rate for one year. This includes personalizing content and advertising. While a P/B of less than 3 would mean it's trading at a discount to the market, different industries have different median P/B values. Want the latest recommendations from Zacks Investment Research? A higher number means the company has more debt to equity, whereas a lower number means it has less debt to equity. A P/S ratio of 2 means you're paying $2 for every $1 of sales the company makes. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One stock that might be an intriguing choice for investors right now is Akebia Therapeutics, Inc. AKBA.This is because this security in the Medical – Drugs space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. Current Cash Flow Growth measures the percent change in the year over year Cash Flow. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Welcome! One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. It is used to help gauge a company's financial health. If you wish to go to ZacksTrade, click OK. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. The 4 Week Price Change displays the percentage price change for the most recently completed 4 weeks (20 trading days). Growth traders and investors will tend to look for growth rates of 20% or higher. The change is made all the more important the closer proximity it is to the stock's earnings date since it is generally believed that the most recent estimates are the most accurate since it's using the most up-to-date information leading up to the report. That is because the Jan 15, 2021 $5.00 Call had some of the highest implied volatility of all equity options today. The median P/B ratio for stocks in the S&P is just over 3. NYSE and AMEX data is at least 20 minutes delayed. This shows the percentage of profit a company earns on its sales. NYSE and AMEX data is at least 20 minutes delayed. This measure is expressed as a percentage. Some investors seek out stocks with the best percentage price change over the last 52 weeks, expecting that momentum to continue. If the volume is too light, in absolute terms or for a relatively large position, it could be difficult to execute a trade. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. The VGM score is based on the trading styles of Growth, VAlue, and Momentum. While the one year change shows the current conditions, the longer look-back period shows how this metric has changed over time and helps put the current reading into proper perspective. Akebia Therapeutics (AKBA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Want the latest recommendations from Zacks Investment Research? Learn more about Zacks Equity Research reports. So the PEG ratio tells you what you're paying for each unit of earnings growth. The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. But they all have their place in the Growth style. in the Information. The Momentum Score takes all of this and more into account. Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports. The technique has proven to be very useful for finding positive surprises. PR Newswire-8.01%. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. This is a longer-term price change metric. See the Full List of Stocks To Beat Earnings. Zacks Style Scores Education - Learn more about the Zacks Style Scores. Cash Flow is a measurement of a company's health. A P/B of 1 means it's selling at its per share book value. The Projected Sales Growth (F1/F0) looks at the estimated growth rate for the current year. A value under 20 is generally considered good. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. This includes measuring aspects of the Income Statement, Statement of Cash Flows, the Balance Sheet, and more. See Zacks' prediction free. Akebia Therapeutics Inc. is a biopharmaceutical company. Is the Options Market Predicting a Spike in Akebia (AKBA) Stock? It takes the consensus sales estimate for the current fiscal year (F1) divided by the sales for the last completed fiscal year (F0) (actual if reported, the consensus if not). Of course, different industries will have different growth rates that are considered good. This time period essentially shows you how the consensus estimate has changed from the time of their last earnings report. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. When comparing this ratio to different stocks in different industries, take note that some businesses are more capital intensive than others. S&P 500 3,881.37 DOW 31,537.35 With 12 weeks representing a meaningful part of a year, this time period will show whether a stock has been enjoying strong investor demand, or if it's in consolidation, or distress. ROE is always expressed as a percentage. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. In short, this is how much a company is worth. This allows the investor to be as broad or as specific as they want to be when selecting stocks. Today, you can download 7 Best Stocks for the Next 30 Days. It's also commonly referred to as a 'liquidity ratio'. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Visit Performance Disclosure for information about the performance numbers displayed above. Debt to Capital (or D/C ratio) is the fraction of debt (including mortgages and long-term leases) to long-term capitalization. A strong weekly advance (especially when accompanied by increased volume) is a sought after metric for putting potential momentum stocks onto one's radar. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.93% per year. Above 1 means it assets are greater than its liabilities. The Value Scorecard table also displays the values for its respective Industry along with the values and Value Score of its three closest peers. The sector with the best average Zacks Rank would be considered the top sector (1 out of 16), which would place it in the top 1% of Zacks Ranked Sectors. AKBA 3.52 0.08 (2.22%). Since there is a fair amount of discretion in what's included and not included in the 'ITDA' portion of this calculation, it is considered a non-GAAP metric. An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's. Less than 1 means its liabilities exceed its short-term assets (cash, inventory, receivables, etc.).